C4 Therapeutics Announces Board and Executive Changes
Ticker: CCCC · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1662579
| Field | Detail |
|---|---|
| Company | C4 Therapeutics, Inc. (CCCC) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $510,000, $150,000, $75,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
Related Tickers: CCCC
TL;DR
C4 Tx board shakeup and comp plan updates filed today.
AI Summary
C4 Therapeutics, Inc. announced on October 15, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans for key personnel. Specific details regarding the financial impact of these changes are not provided in this initial filing.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can sometimes precede significant strategic shifts or financial adjustments, warranting closer investor scrutiny.
Key Players & Entities
- C4 Therapeutics, Inc. (company) — Registrant
- October 15, 2024 (date) — Date of earliest event reported
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates "Departure of Directors or Certain Officers" as an item, but does not specify the exact roles or individuals in this section of the 8-K.
Were there any new directors elected to the board?
Yes, the filing lists "Election of Directors" as an item, indicating new directors have been appointed.
Are there details on the new compensatory arrangements for officers?
The filing mentions "Compensatory Arrangements of Certain Officers" as an item, suggesting updates to compensation plans are being disclosed.
Does this filing include financial statements?
Yes, "Financial Statements and Exhibits" is listed as an item, indicating that financial information and exhibits are part of this filing.
What is the primary purpose of this Form 8-K filing?
This Form 8-K is a current report filed to disclose material events, specifically focusing on changes in directors/officers, elections, and executive compensation, as well as Regulation FD disclosures and financial statements/exhibits.
Filing Stats: 1,436 words · 6 min read · ~5 pages · Grade level 10.4 · Accepted 2024-10-15 16:11:54
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CCCC The Nasdaq Glo
- $510,000 — e will receive an annual base salary of $510,000, a sign-on bonus of $150,000, a relocat
- $150,000 — salary of $510,000, a sign-on bonus of $150,000, a relocation allowance of up to $75,00
- $75,000 — 50,000, a relocation allowance of up to $75,000, and an opportunity to earn a performan
Filing Documents
- cccc-20241015.htm (8-K) — 37KB
- c4tfisherconsultingagree.htm (EX-10.1) — 4KB
- cccc-20241015xexx991.htm (EX-99.1) — 16KB
- c4tfisherconsultingagree001.jpg (GRAPHIC) — 203KB
- c4tfisherconsultingagree002.jpg (GRAPHIC) — 230KB
- c4tfisherconsultingagree003.jpg (GRAPHIC) — 243KB
- c4tfisherconsultingagree004.jpg (GRAPHIC) — 260KB
- c4tfisherconsultingagree005.jpg (GRAPHIC) — 217KB
- c4tfisherconsultingagree006.jpg (GRAPHIC) — 244KB
- c4tfisherconsultingagree007.jpg (GRAPHIC) — 249KB
- c4tfisherconsultingagree008.jpg (GRAPHIC) — 198KB
- c4tfisherconsultingagree009.jpg (GRAPHIC) — 41KB
- c4tfisherconsultingagree010.jpg (GRAPHIC) — 120KB
- c4tfisherconsultingagree011.jpg (GRAPHIC) — 26KB
- c4tfisherconsultingagree012.jpg (GRAPHIC) — 27KB
- c4tlogo1.jpg (GRAPHIC) — 9KB
- 0001628280-24-042833.txt ( ) — 3039KB
- cccc-20241015.xsd (EX-101.SCH) — 2KB
- cccc-20241015_lab.xml (EX-101.LAB) — 22KB
- cccc-20241015_pre.xml (EX-101.PRE) — 13KB
- cccc-20241015_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. The Company issued a press release on October 15, 2024, announcing Dr. Mahaney's appointment. The press release is attached hereto as Exhibit 99.1. Pursuant to General Instruction B.2. to Form 8-K, the information set forth in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form. Exhibit Number Description 10.1 Consulting Agreement dated as of October 15, 2024, between C4 Therapeutics, Inc. and Stewart Fisher 99.1 Press release issued October 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. C4 Therapeutics, Inc. Date: October 15 , 2024 By: /s/ Jolie M. Siegel Jolie M. Siegel Chief Legal Officer